For the study, five different assays were compared in the health system laboratory for identifying C. diff. Researchers then evaluated the result of molecular versus non-molecular tests. Results showed the molecular methods detected 35-54 percent more patients who were positive for C. diff than non-molecular tests.
Read the news release about the Lifespan study on molecular tests for C. diff infections.
Related Articles on C. Diff:
New Policies at Texas VA Hospital Lead to 82% Decrease of Infection by Multidrug-Resistant Organisms
C. Diff Increases Risk of Death 6-Fold in Inflammatory Bowel Disease Patients
Wound Dressing With Silver Kills MRSA, Other Antibiotic-Resistance ‘Superbugs’
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
